Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박시훈 | - |
dc.date.accessioned | 2016-08-28T12:08:55Z | - |
dc.date.available | 2016-08-28T12:08:55Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0009-7322 | - |
dc.identifier.other | OAK-8456 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222352 | - |
dc.description.abstract | BACKGROUND-: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month DAPT would be noninferior to 12-month DAPT after implantation of drug-eluting stents. METHODS AND RESULTS-: We randomly assigned 1443 patients undergoing implantation of drug-eluting stents to receive 6- or 12-month DAPT (in a 1:1 ratio). The primary end point was a target vessel failure, defined as the composite of cardiac death, myocardial infarction, or ischemia-driven target vessel revascularization at 12 months. Rates of target vessel failure at 12 months were 4.8% in the 6-month DAPT group and 4.3% in the 12-month DAPT group (the upper limit of 1-sided 95% confidence interval, 2.4%; P=0.001 for noninferiority with a predefined noninferiority margin of 4.0%). Although stent thrombosis tended to occur more frequently in the 6-month DAPT group than in the 12-month group (0.9% versus 0.1%; hazard ratio, 6.02; 95% confidence interval, 0.72-49.96; P=0.10), the risk of death or myocardial infarction did not differ in the 2 groups (2.4% versus 1.9%; hazard ratio, 1.21; 95% confidence interval, 0.60-2.47; P=0.58). In the prespecified subgroup analysis, target vessel failure occurred more frequently in the 6-month DAPT group than in the 12-month group (hazard ratio, 3.16; 95% confidence interval, 1.42-7.03; P=0.005) among diabetic patients. CONCLUSIONS-: Six-month DAPT did not increase the risk of target vessel failure at 12 months after implantation of drug-eluting stents compared with 12-month DAPT. However, the noninferiority margin was wide, and the study was underpowered for death or myocardial infarction. Our results need to be confirmed in larger trials. CLINICAL TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00698607. © 2011 American Heart Association, Inc. | - |
dc.language | English | - |
dc.title | Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 125 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 505 | - |
dc.relation.lastpage | 513 | - |
dc.relation.journaltitle | Circulation | - |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.111.059022 | - |
dc.identifier.wosid | WOS:000300252800018 | - |
dc.identifier.scopusid | 2-s2.0-84856452781 | - |
dc.author.google | Gwon H.-C. | - |
dc.author.google | Hahn J.-Y. | - |
dc.author.google | Park K.W. | - |
dc.author.google | Song Y.B. | - |
dc.author.google | Chae I.-H. | - |
dc.author.google | Lim D.-S. | - |
dc.author.google | Han K.-R. | - |
dc.author.google | Choi J.-H. | - |
dc.author.google | Choi S.-H. | - |
dc.author.google | Kang H.-J. | - |
dc.author.google | Koo B.-K. | - |
dc.author.google | Ahn T. | - |
dc.author.google | Yoon J.-H. | - |
dc.author.google | Jeong M.-H. | - |
dc.author.google | Hong T.-J. | - |
dc.author.google | Chung W.-Y. | - |
dc.author.google | Choi Y.-J. | - |
dc.author.google | Hur S.-H. | - |
dc.author.google | Kwon H.-M. | - |
dc.author.google | Jeon D.-W. | - |
dc.author.google | Kim B.-O. | - |
dc.author.google | Park S.-H. | - |
dc.author.google | Lee N.-H. | - |
dc.author.google | Jeon H.-K. | - |
dc.author.google | Jang Y. | - |
dc.author.google | Kim H.-S. | - |
dc.contributor.scopusid | 박시훈(9737584900;57191750840) | - |
dc.date.modifydate | 20221123115020 | - |